Form 8-K - Current report

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): August 6, 2024

Enhabit, Inc.

(Exact name of registrant as specified in its charter)


Delaware	001-41406	47-2409192
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

6688 N. Central Expressway, Suite 1300, Dallas, Texas 75206

(Address of principal executive offices, including zip code)

(214) 239-6500

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


☐			Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	EHAB	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.*

On August 6, 2024, Enhabit, Inc. (the “Company”) issued a press release reporting the financial results of the Company for the quarter ended June 30, 2024 (the “Earnings Press Release”). A copy of the Earnings Press Release is attached to this report as Exhibit 99.1 and incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.*

A copy of the supplemental information which will be discussed during the Company’s earnings call at 10:00 a.m. Eastern Time on Wednesday, August 7, 2024, is attached to this report as Exhibit 99.2 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.


Exhibit Number						Description
99.1						Earnings Press Release of Enhabit, Inc., dated August 6 , 2024.*
99.2						Supplemental information provided in connection with the second quarter 2024 earnings call of Enhabit, Inc.*
104						Cover Page Interactive Data File - the cover page iXBRL tags are embedded within the Inline XBRL document

* The information in Item 2.02 and 7.01, including Exhibit 99.1 and Exhibit 99.2, is being “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, unless specifically identified as being incorporated therein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.


ENHABIT, INC.
By:	/s/ Dylan C. Black
	Name:	Dylan C. Black
	Title:	General Counsel

Dated: August 6, 2024

Exhibit 99.1

Enhabit Reports Second Quarter 2024 Financial Results

Company to host a conference call tomorrow, August 7, 2024, at 10 a.m. EDT

DALLAS, TX – August 6, 2024 – Enhabit, Inc. (NYSE: EHAB), a leading home health and hospice care provider, today reported its results of operations for the second quarter ended June 30, 2024.

“The second quarter marked our third sequential quarter demonstrating the success of our strategies,” said Enhabit’s President and Chief Executive Officer Barb Jacobsmeyer. “In our home health segment, our total admissions growth of 6.4% was driven by our payor innovation strategy and our focus on improved utilization of our clinical resources. In our hospice segment, we continued to make steady progress in growing our census, with average daily census increasing each month since January 2024. Our focus on recruitment and retention continues to position us for long-term growth, and we remain confident in the long-range growth potential for Enhabit.”

QUARTERLY PERFORMANCE - CONSOLIDATED

•Net service revenue of $260.6 million

•Net loss attributable to Enhabit, Inc. of $0.2 million

•Adjusted EBITDA of $25.2 million

•Earnings per share of $0.00

•Adjusted earnings per share of $0.07

RECENT COMPANY HIGHLIGHTS

•Non-Medicare admissions grew 25.2%, driving total admission growth of 6.4% year over year

◦43% of non-Medicare visits are now in payor innovation contracts at improved rates

•30-day hospitalization readmission rate in home health is 23.3% better than the national average

•Hospice average daily census increased 2.7% year over year

◦Average daily census increased sequentially every month since January

•53.2% better than the national average for hospice patient visits in last days of life

•Reduced bank debt by $15 million in the quarter

•Opened one home health de novo location in Florida in April

FINANCIAL RESULTS

Consolidated


($ in millions, except per share data)	Q2								'24 vs. '23
	2024				2023
Home health net service revenue	$	210.2			$	213.8			(1.7)%
Hospice net service revenue	50.4				48.5				3.9%
Total net service revenue	$	260.6			$	262.3			(0.6)%

	% of revenue				% of revenue
Cost of service	50.6%		$	131.8	51.7%		$	135.5	(2.7)%
Gross margin	49.4%		128.8		48.3%		126.8		1.6%
General and administrative expenses	39.5%		103.0		39.2%		102.7		0.3%
Total operating expenses	90.1%		$	234.8	90.8%		$	238.2	(1.4)%


Other income	—				(0.1)
Net income attributable to noncontrolling interests	0.6				0.3

Adjusted EBITDA	$	25.2			$	23.9			5.4%
Adjusted EBITDA margin	9.7%				9.1%
Impairment of goodwill	$	—			$	85.8			(100.0)%
Net loss attributable to Enhabit, Inc.	$	(0.2)			$	(74.4)			(99.7)%
Reported diluted EPS	$	—			$	(1.49)			(100.0)%
Adjusted EPS	$	0.07			$	0.04			75.0%

Consolidated Adjusted EBITDA grew 5.4% year over year through cost management in home health and revenue growth in hospice.

SEGMENT RESULTS

Home Health


($ in millions)	Q2				'24 vs. '23
	2024		2023
Net service revenue:
Medicare	$	121.7	$	139.4	(12.7)%
Non-Medicare	86.3		71.8		20.2%
Private duty(1)	2.2		2.6		(15.4)%
Home health net service revenue	210.2		213.8		(1.7)%
Cost of service	106.9		111.4		(4.0)%
Gross margin	49.1%		47.9%
General and administrative expenses	58.6		59.4		(1.3)%
Other income	—		(0.1)		(100.0)%
Net income attributable to noncontrolling interests	0.5		0.3		66.7%
Adjusted EBITDA	$	44.2	$	42.8	3.3%
% Adj. EBITDA margin	21.0%		20.0%
Operational metrics (actual amounts)
Medicare:
Admissions	24,015		26,845		(10.5)%
Recertifications	16,639		19,884		(16.3)%
Completed episodes	41,620		47,528		(12.4)%
Visits	597,742		691,857		(13.6)%
Visits per episode	14.4		14.6		(1.4)%
Revenue per episode	$	2,924	$	2,933	(0.3)%
Non-Medicare:
Admissions	30,209		24,130		25.2%
Recertifications	14,587		13,458		8.4%
Visits	581,326		514,008		13.1%

Total:
Admissions	54,224		50,975		6.4%
Same-store total admissions growth					6.2%
Recertifications	31,226		33,342		(6.3)%
Same-store total recertifications growth					(6.5)%


Visits	1,179,068		1,205,865		(2.2)%


Visits per episode	14.0		14.6		(4.1)%
Cost per visit	$	89	$	91	(2.2)%
(1) Private duty represents long-term comprehensive hourly nursing medical care.

Non-Medicare admissions grew 25.2%, driving total admissions growth of 6.4% year over year. Revenue declined $3.6 million, or 1.7%, year over year primarily due to lower Medicare volume as a result of lower recertifications. The net impact of the payor mix shift year over year was a positive $1 million.

Adjusted EBITDA increased $1.4 million, or 3.3% year over year primarily due to lower cost per visit. Cost per visit decreased 2.2% year over year primarily due to a reduction in contract labor and favorable experience in workers’ compensation and group medical claims.

Hospice


($ in millions)	Q2				'24 vs. '23
	2024		2023
Net service revenue	$	50.4	$	48.5	3.9%
Cost of service	24.9		24.1		3.3%
Gross margin	50.6%		50.3%
General and administrative expenses	16.3		16.1		1.2%
Net income attributable to noncontrolling interests	0.1		—		NM
Adjusted EBITDA	$	9.1	$	8.3	9.6%
% Adj. EBITDA margin	18.1%		17.1%
Operational metrics (actual amounts)
Total admissions	2,888		2,837		1.8%
Same-store total admissions growth					(0.2)%
Patient days	320,026		311,465		2.7%
Discharged average length of stay	108		108		—%
Average daily census	3,517		3,423		2.7%
Revenue per patient day	$	157	$	156	0.6%
Cost per patient day	$	78	$	77	1.3%
References in the financial tables to percentage changes that are not meaningful are denoted by “NM”.

Net service revenue increased $1.9 million, or 3.9%, year over year due to increased Medicare reimbursement rates and an increase in patient days. Average daily census increased 3.7% sequentially and has increased sequentially every month since January 2024. Adjusted EBITDA increased $0.8 million, or 9.6%, year over year primarily due to increased revenue. Cost per day increased 1.3% year over year primarily due to increased costs associated with patient supplies, including durable medical equipment and pharmacy.

GUIDANCE

The Company updated its full-year 2024 guidance as follows:

($ in millions, except per share data)

2024 Previous Guidance

2024 Updated Guidance

Net service revenue

$1,076 to $1,102

$1,050 to $1,063

Adjusted EBITDA

$98 to $110

$100 to $106

Adjusted EPS

$0.12 to $0.43

$0.19 to $0.37

For additional considerations regarding the Company’s 2024 guidance ranges, see the supplemental information posted on the Company’s website at http://investors.ehab.com.

CONFERENCE CALL INFORMATION

The Company will host an investor conference call at 10 a.m. EDT on August 7, 2024 to discuss its results for the second quarter of 2024. To access the live call by phone, dial toll-free (888) 660-6150 or international (929) 203-0843; the conference ID is 5248158. A simultaneous webcast of the call, along with supplemental information, may be accessed by visiting https://events.q4inc.com/attendee/154318091. Following the call, a replay will be available on the Company’s website at http://investors.ehab.com.

ABOUT ENHABIT HOME HEALTH & HOSPICE

Enhabit Home Health & Hospice (Enhabit, Inc.) is a leading national home health and hospice provider working to expand what's possible for patient care in the home. Enhabit’s team of clinicians supports patients and their families where they are most comfortable, with a nationwide footprint spanning 256 home health locations and 112 hospice locations across 34 states. Enhabit leverages advanced technology and compassionate teams to deliver extraordinary patient care. For more information, visit ehab.com.

OTHER INFORMATION

Note regarding presentation and reconciliation of non-GAAP financial measures

The financial data contained in this press release and supplemental information includes non-GAAP (generally accepted accounting principles (GAAP)) financial measures as defined in Regulation G under the Securities Exchange Act of 1934, including Adjusted EBITDA, Adjusted EBITDA margin, Adjusted EPS, and Adjusted free cash flow. See “Supplemental Non-GAAP Information” for reconciliations of the non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with GAAP. Additionally, our Form 10-Q for the three and six months ended June 30, 2024, provides further information regarding “unusual or nonrecurring items that are not typical of ongoing operations,” a reconciliation item in our Adjusted EBITDA calculation. Such non-GAAP financial measures exclude significant components in understanding and assessing financial performance and should therefore not be considered superior to, as a substitute for or alternative to the GAAP financial measures presented in this press release. The non-GAAP financial measures in the press release may differ from similar measures used by other companies.

The Company is unable to reconcile the guidance for Adjusted EBITDA and Adjusted EPS to their corresponding GAAP measures without unreasonable effort due to the inherent difficulty in predicting, with reasonable certainty, the future impact of items that are outside the control of the Company or otherwise non-indicative of its ongoing operating performance. Accordingly, the Company relies on the exception provided by Item 10(e)(1)(i)(B) of Regulation S-K. Such items include, but are not limited to, gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); and items related to corporate and facility restructurings. For the same reasons, the Company is unable to address the probable significance of the unavailable information.

Note regarding presentation of same-store comparisons

The Company uses “same-store” comparisons to explain the changes in certain performance metrics and line items within its financial statements. Same-store comparisons are calculated based on home health and hospice locations open throughout both the full current period and the immediately prior period presented. These comparisons include the financial results of market consolidation transactions in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on the Company’s results of operations.

Enhabit, Inc. and Subsidiaries

Condensed Consolidated Statements of Income

(Unaudited)


	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023
	($ in millions, except per share data)
Net service revenue	$	260.6	$	262.3	$	523.0	$	527.4
Cost of service, excluding depreciation and amortization	131.8		135.5		266.0		268.1

General and administrative expenses	110.0		107.8		217.5		218.3
Depreciation and amortization	7.6		7.7		15.4		15.5
Impairment of goodwill	—		85.8		—		85.8
Operating income (loss)	11.2		(74.5)		24.1		(60.3)
Interest expense and amortization of debt discounts and fees	10.9		10.3		22.0		19.8

Other income	—		(0.1)		—		(0.1)
Income (loss) before income taxes and noncontrolling interests	0.3		(84.7)		2.1		(80.0)
Income tax (benefit) expense	(0.1)		(10.6)		0.8		(9.1)
Net income (loss)	0.4		(74.1)		1.3		(70.9)
Less: Net income attributable to noncontrolling interests	0.6		0.3		1.3		0.8
Net loss attributable to Enhabit, Inc.	$	(0.2)	$	(74.4)	$	—	$	(71.7)

Weighted average common shares outstanding:
Basic	50.1		49.8		50.1		49.8
Diluted	50.1		49.8		50.1		49.8

Loss per common share:
Basic loss per share attributable to Enhabit, Inc. common stockholders	$	—	$	(1.49)	$	—	$	(1.44)
Diluted loss per share attributable to Enhabit, Inc. common stockholders	$	—	$	(1.49)	$	—	$	(1.44)

Enhabit, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(Unaudited)


	June 30, 2024		December 31, 2023
	($ in millions)
Assets
Current assets:
Cash and cash equivalents	$	28.5	$	27.4
Restricted cash	1.7		2.4
Accounts receivable, net of allowances	166.0		164.7




Prepaid expenses and other current assets	10.6		15.6
Total current assets	206.8		210.1
Property and equipment, net	21.6		19.0
Operating lease right-of-use assets	55.0		57.5
Goodwill	1,061.7		1,061.7
Intangible assets, net	69.0		80.0
Other long-term assets	4.9		5.3
Total assets	$	1,419.0	$	1,433.6
Liabilities and stockholders’ equity
Current liabilities:
Current portion of long-term debt	$	23.0	$	22.5
Current operating lease liabilities	11.0		11.8
Accounts payable	8.5		7.6
Accrued payroll	37.0		38.5
Refunds due patients and other third-party payors	10.4		8.2


Accrued medical insurance	9.8		8.4


Other current liabilities	40.4		40.7
Total current liabilities	140.1		137.7
Long-term debt, net of current portion	512.7		530.1
Long-term operating lease liabilities, net of current portion	44.3		45.7
Deferred income tax liabilities	16.4		17.1
Other long-term liabilities	0.1		1.3
Total liabilities	713.6		731.9

Redeemable noncontrolling interests	5.0		5.0
Stockholders’ equity:
Total Enhabit, Inc. stockholders’ equity	674.3		669.7
Noncontrolling interests	26.1		27.0
Total stockholders’ equity	700.4		696.7
Total liabilities and stockholders’ equity	$	1,419.0	$	1,433.6

Enhabit, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(Unaudited)


	Six Months Ended June 30,
	2024		2023
	($ in millions)
Cash flows from operating activities:
Net income (loss)	$	1.3	$	(70.9)
Adjustments to reconcile net income (loss) to net cash provided by operating activities—
Depreciation and amortization	15.4		15.5
Amortization of debt related costs	0.7		0.5


Impairment of goodwill	—		85.8
Stock-based compensation	4.0		4.1
Deferred tax benefit	(1.1)		(11.0)
Other	(0.1)		0.9
Changes in assets and liabilities, net of acquisitions—
Accounts receivable, net of allowances	(1.3)		1.9
Prepaid expenses and other assets	5.9		19.2
Accounts payable	0.1		1.5
Accrued payroll	(1.5)		(2.6)
Other liabilities	3.5		(5.7)
Net cash provided by operating activities	26.9		39.2
Cash flows from investing activities:
Acquisition of businesses, net of cash acquired	—		(2.8)
Purchases of property and equipment, including capitalized software costs	(2.5)		(1.7)

Other	0.8		0.5
Net cash used in investing activities	(1.7)		(4.0)
Cash flows from financing activities:
Principal payments on term loan facility	(10.0)		(10.0)


Principal payments on revolving credit facility	(10.0)		(10.0)



Distributions paid to noncontrolling interests of consolidated affiliates	(2.2)		(2.5)



Other	(2.6)		(3.4)
Net cash used in financing activities	(24.8)		(25.9)
Increase in cash, cash equivalents, and restricted cash	0.4		9.3
Cash, cash equivalents, and restricted cash at beginning of period	29.8		27.2
Cash, cash equivalents, and restricted cash at end of period	$	30.2	$	36.5

Enhabit, Inc. and Subsidiaries

Supplemental Non-GAAP Information

(Unaudited)


Reconciliation of Diluted Earnings Per Share to Adjusted Earnings Per Share

	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023
Diluted earnings per share, as reported	$	—	$	(1.49)	$	—	$	(1.44)
Adjustments, net of tax:
Impairment of goodwill	—		1.50		—		1.50
Unusual or nonrecurring items that are not typical of ongoing operations(1)	0.07		0.03		0.13		0.07
Income tax adjustments(2)	—		—		0.01		0.01
Adjusted earnings per share	$	0.07	$	0.04	$	0.14	$	0.14

(1) Unusual or nonrecurring items in the three and six months ended June 30, 2024 include costs associated with shareholder activism, the strategic review process and nonroutine litigation; in the three and six months ended June 30, 2023, they include nonroutine litigation and shareholder activism.

(2) Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation.

Enhabit, Inc. and Subsidiaries

Supplemental Non-GAAP Information

(Unaudited)


Reconciliation of Adjusted EBITDA to Adjusted Earnings Per Share

	Three Months Ended June 30,
	2024
			Adjustments
	As Reported		Unusual or Nonrecurring Items That are Not Typical of Ongoing Operations		As Adjusted
	($ in millions, except per share data)
Adjusted EBITDA(1)	$	25.2	$	—	$	25.2

Interest expense and amortization of debt discounts and fees	(10.9)		—		(10.9)
Depreciation and amortization	(7.6)		—		(7.6)
Stock-based compensation	(2.2)		—		(2.2)
Unusual or nonrecurring items that are not typical of ongoing operations(2)	(4.8)		4.8		—


(Loss) income before income taxes	(0.3)		4.8		4.5
Income tax benefit (expense)	0.1		(1.3)		(1.2)
Net (loss) income attributable to Enhabit, Inc.	$	(0.2)	$	3.5	$	3.3
Diluted EPS	$	—	$	0.07	$	0.07
Diluted shares	50.1				50.1

(1) Reconciliation to GAAP provided below.

(2) Unusual or nonrecurring items in Q2 2024 include costs associated with shareholder activism, the strategic review process and nonroutine litigation.

Enhabit, Inc. and Subsidiaries

Supplemental Non-GAAP Information

(Unaudited)


Reconciliation of Adjusted EBITDA to Adjusted Earnings Per Share

	Three Months Ended June 30,
	2023
			Adjustments
	As Reported			Impairment of Goodwill		Unusual or Nonrecurring Items That are Not Typical of Ongoing Operations		Income Tax Adjustments(3)		As Adjusted
	($ in millions, except per share data)
Adjusted EBITDA(1)	$	23.9		$	—	$	—	$	—	$	23.9
Interest expense and amortization of debt discounts and fees	(10.3)			—		—		—		(10.3)
Depreciation and amortization	(7.7)			—		—		—		(7.7)
Gain on disposal of assets	0.1			—		—		—		0.1
Impairment of goodwill	(85.8)			85.8		—		—		—
Stock-based compensation	(2.6)			—		—		—		(2.6)
Unusual or nonrecurring items that are not typical of ongoing operations(2)	(2.6)			—		2.6		—		—
(Loss) income before income taxes	(85.0)			85.8		2.6		—		3.4
Income tax benefit (expense)	10.6			(11.1)		(1.0)		0.1		(1.4)
Net (loss) income attributable to Enhabit, Inc.	$	(74.4)		$	74.7	$	1.6	$	0.1	$	2.0
Diluted EPS	$	(1.49)		$	1.50	$	0.03	$	—	$	0.04
Diluted shares	49.8									49.8

(1) Reconciliation to GAAP provided below.

(2) Unusual or nonrecurring items in Q2 2023 include costs associated with nonroutine litigation and shareholder activism.

(3) Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation.

Enhabit, Inc. and Subsidiaries

Supplemental Non-GAAP Information

(Unaudited)


Reconciliation of Adjusted EBITDA to Adjusted Earnings Per Share

	Six Months Ended June 30,
	2024
			Adjustments
	As Reported		Unusual or Nonrecurring Items That are Not Typical of Ongoing Operations		Income Tax Adjustments(3)		As Adjusted
	($ in millions, except per share data)
Adjusted EBITDA(1)	$	50.5	$	—	$	—	$	50.5
Interest expense and amortization of debt discounts and fees	(22.0)		—		—		(22.0)
Depreciation and amortization	(15.4)		—		—		(15.4)

Gain on disposal of assets	0.2		—		—		0.2
Stock-based compensation	(4.0)		—		—		(4.0)
Unusual or nonrecurring items that are not typical of ongoing operations(2)	(8.5)		8.5		—		—

Income before income taxes	0.8		8.5		—		9.3
Income tax expense	(0.8)		(2.2)		0.6		(2.4)
Net income attributable to Enhabit, Inc.	$	—	$	6.3	$	0.6	$	6.9
Diluted EPS	$	—	$	0.13	$	0.01	$	0.14
Diluted shares	50.1						50.1

(1) Reconciliation to GAAP provided below.

(2) Unusual or nonrecurring items in 2024 include costs associated with shareholder activism, the strategic review process and nonroutine litigation.

(3) Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation.

Enhabit, Inc. and Subsidiaries

Supplemental Non-GAAP Information

(Unaudited)


Reconciliation of Adjusted EBITDA to Adjusted Earnings Per Share

	Six Months Ended June 30,
	2023
			Adjustments
	As Reported			Impairment of Goodwill		Unusual or Nonrecurring Items That are Not Typical of Ongoing Operations		Income Tax Adjustments(3)		As Adjusted
	($ in millions, except per share data)
Adjusted EBITDA(1)	$	49.2		$	—	$	—	$	—	$	49.2
Interest expense and amortization of debt discounts and fees	(19.8)			—		—		—		(19.8)
Depreciation and amortization	(15.5)			—		—		—		(15.5)
Gain on disposal of assets	0.1			—		—		—		0.1
Impairment of goodwill	(85.8)			85.8		—		—		—
Stock-based compensation	(4.1)			—		—		—		(4.1)
Unusual or nonrecurring items that are not typical of ongoing operations(2)	(4.9)			—		4.9		—		—

(Loss) income before income taxes	(80.8)			85.8		4.9		—		9.9
Income tax benefit (expense)	9.1			(11.1)		(1.6)		0.5		(3.1)
Net (loss) income attributable to Enhabit, Inc.	$	(71.7)		$	74.7	$	3.3	$	0.5	$	6.8
Diluted EPS	$	(1.44)		$	1.50	$	0.07	$	0.01	$	0.14
Diluted shares	49.8									49.8

(1) Reconciliation to GAAP provided below.

(2) Unusual or nonrecurring items in 2023 include costs associated with nonroutine litigation and shareholder activism.

(3) Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation.

Enhabit, Inc. and Subsidiaries

Supplemental Non-GAAP Information

(Unaudited)


Reconciliation of Net Income (Loss) to Adjusted EBITDA

	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023
	($ in millions)
Net income (loss)	$	0.4	$	(74.1)	$	1.3	$	(70.9)
Interest expense and amortization of debt discounts and fees	10.9		10.3		22.0		19.8
Income tax (benefit) expense	(0.1)		(10.6)		0.8		(9.1)
Depreciation and amortization	7.6		7.7		15.4		15.5
Gain on disposal of assets	—		(0.1)		(0.2)		(0.1)
Impairment of goodwill	—		85.8		—		85.8
Stock-based compensation	2.2		2.6		4.0		4.1
Net income attributable to noncontrolling interests	(0.6)		(0.3)		(1.3)		(0.8)
Unusual or nonrecurring items that are not typical of ongoing operations(1)	4.8		2.6		8.5		4.9
Adjusted EBITDA	$	25.2	$	23.9	$	50.5	$	49.2


Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA

	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023
	($ in millions)
Net cash provided by operating activities	$	9.6	$	9.6	$	26.9	$	39.2
Interest expense, excluding amortization of debt discounts and fees	10.6		10.1		21.3		19.3
Current portion of income tax expense	0.5		0.7		1.9		1.9
Change in assets and liabilities, excluding derivative instrument	0.3		1.2		(6.9)		(15.0)
Net income attributable to noncontrolling interests	(0.6)		(0.3)		(1.3)		(0.8)
Unusual or nonrecurring items that are not typical of ongoing operations(1)	4.8		2.6		8.5		4.9
Other	—		—		0.1		(0.3)



Adjusted EBITDA	$	25.2	$	23.9	$	50.5	$	49.2

Enhabit, Inc. and Subsidiaries

Supplemental Non-GAAP Information

(Unaudited)


Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow

	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023
	($ in millions)
Net cash provided by operating activities	$	9.6	$	9.6	$	26.9	$	39.2
Unusual or nonrecurring items that are not typical of ongoing operations(1)	4.8		2.6		8.5		4.9
Capital expenditures for maintenance	(0.7)		(1.1)		(2.5)		(1.7)
Other working capital adjustments	(1.1)		(0.5)		(1.7)		(1.0)
Distributions paid to noncontrolling interests of consolidated affiliates	(2.2)		—		(2.2)		(2.5)

Adjusted free cash flow	$	10.4	$	10.6	$	29.0	$	38.9


Reconciliation of Gross Margin to Adjusted EBITDA Margin

	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023

Gross margin as a percentage of revenue	49.4	%	48.3	%	49.1	%	49.2	%
General and administrative expenses	(42.2)	%	(41.1)	%	(41.6)	%	(41.4)	%
Stock-based compensation	0.9	%	1.0	%	0.8	%	0.8	%
Noncontrolling interests	(0.2)	%	(0.1)	%	(0.2)	%	(0.2)	%
Unusual or nonrecurring items that are not typical of ongoing operations(1)	1.8	%	1.0	%	1.6	%	0.9	%

Adjusted EBITDA margin	9.7	%	9.1	%	9.7	%	9.3	%

FORWARD-LOOKING STATEMENTS

Statements contained in this press release which are not historical facts, such as those relating to future events, projections, financial guidance, legislative or regulatory developments, strategy or growth opportunities, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All such estimates, projections and forward-looking information speak only as of the date hereof, and Enhabit undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events or otherwise. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties, many of which are beyond our control. Actual events or results may differ materially from the results anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by the Company include, but are not limited to, our ability to execute on our strategic plans; regulatory and other developments impacting the markets for our services; changes in reimbursement rates; general economic conditions; changes in the episodic versus non-episodic mix of our payors, the case mix of our patients, and payment methodologies; our ability to attract and retain key management personnel and health care professionals; potential disruptions or breaches of our or our vendors’, payors’, and other contract counterparties’ information systems; the outcome of litigation; our ability to successfully complete and integrate de novo locations, acquisitions, investments, and joint ventures; our ability to successfully integrate technology in our operations; and our ability to control costs, particularly labor and employee benefit costs. Additional information regarding risks and factors that could cause actual results to differ materially from those expressed or implied by any forward-looking statement in this press release are described in reports filed with the SEC, including our annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, copies of which are available on the Company’s website at http://investors.ehab.com.

Investor relations contact

Crissy Carlisle

investorrelations@ehab.com

469-860-6061

Media contact

Erin Volbeda

media@ehab.com

972-338-5141

Second Quarter Earnings Call Supplemental Information August 7, 2024

Enhabit Home Health & Hospice 2 Disclaimer Forward looking statements Statements contained in this presentation which are not historical facts, such as those relating to future events, projections, financial guidance, legislative or regulatory developments, strategy or growth opportunities, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All such estimates, projections, and forward-looking information speak only as of the date hereof, and Enhabit undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events, or otherwise. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties, many of which are beyond our control. Actual events or results may differ materially from the results anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by the Company include, but are not limited to, our ability to execute on our strategic plans; regulatory and other developments impacting the markets for our services; changes in reimbursement rates; general economic conditions; changes in the episodic versus non-episodic mix of our payors, the case mix of our patients and payment methodologies; our ability to attract and retain key management personnel and healthcare professionals; potential disruptions or breaches of our or our vendors’, payors’, and other contract counterparties’ information systems; the outcome of litigation; our ability to successfully complete and integrate de novo locations, acquisitions, investments, and joint ventures; our ability to successfully integrate technology in our operations; and our ability to control costs, particularly labor and employee benefit costs. Additional information regarding risks and factors that could cause actual results to differ materially from those expressed or implied by any forward-looking statement in this presentation are described in reports filed with the SEC, including our annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, copies of which are available on the Company’s website at http://investors.ehab.com. Note regarding presentation of non-GAAP financial measures This presentation includes certain “non-GAAP financial measures” as defined in Regulation G under the Securities Exchange Act of 1934, including Adjusted EBITDA, Adjusted EBITDA margin, Adjusted earnings per share, and Adjusted free cash flow. Reconciliations of these non-GAAP financial measures to the most directly comparable financial measures calculated in accordance with GAAP are presented at the end of this presentation. Our Form 8-K, filed with the SEC as of the date of this presentation, provides further explanation and disclosure regarding Enhabit’s use of non-GAAP financial measures and should be read in conjunction with this supplemental information. Additionally, our Form 10-Q for the three months ended June 30, 2024, provides further information regarding "unusual or nonrecurring items that are not typical of ongoing operations," a reconciliation item in our Adjusted EBITDA calculation. Note regarding presentation of same-store comparisons The Company uses “same-store” comparisons to explain the changes in certain performance metrics and line items within its financial statements. Same-store comparisons are calculated based on home health and hospice locations open throughout both the full current period and the immediately prior period presented. These comparisons include the financial results of market consolidation transactions in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on the Company’s results of operations.

Contents Results at a Glance 4 Consolidated Results 5-6 Clinical Expertise and High-Quality Outcomes 7 Payor Innovation 8-9 De Novos 10 Home Health Segment 11-12 Hospice Segment 13-14 Consolidated Adjusted EBITDA 15 Debt and Liquidity 16 Adjusted Free Cash Flow 17 Guidance 18-19 Adjusted Free Cash Flow Assumptions and Uses of Free Cash Flow 20-21 Appendix, Including Company Overview & Reconciliations to GAAP 22-41

Enhabit Home Health & Hospice 4 Non-Medicare admissions grew 25.2%, driving total admissions growth of 6.4% year over year. 43% of non-Medicare visits are now in payor innovation contracts at improved rates. Cost per visit decreased 2.2% year over year. 30-day hospital readmission rate 23.3% better than national average Average daily census increased 2.7% year over year. Average daily census increased sequentially every month since January. Admissions increased 1.8% year over year Adjusted EBITDA grew 9.6% year over year. Cost per day increased 1.3% year over year. 53.2% better than the national average for patient visits in the last days of life Reconciliations to GAAP provided in Appendix Results at a Glance Consolidated Adjusted EBITDA grew 5.4% year over year through cost management in home health and revenue growth in hospice. Continued success in recruitment and retention of nurses Reduced bank debt by $15 million in the quarter; bank debt down $30 million year over year Home Health Hospice Consolidated $260.6M Net service revenue $0.2M $0.00 Net loss attributable to Enhabit, Inc. Reported EPS $25.2M $0.07 Adjusted EBITDA Adjusted EPS 54,224 2,888 Home Health Admissions Hospice Admissions 41,620 3,517 Home Health Medicare completed episodes Hospice Average daily census $2,924 $157 Home Health Medicare revenue per episode Hospice Revenue per patient day $89 $78 Home Health Cost per visit Hospice Cost per patient day

Enhabit Home Health & Hospice 5 Consolidated Results ($ in millions, except per share data) Q2 '24 vs. '232024 2023 Home health net service revenue $210.2 $213.8 (1.7) % Hospice net service revenue 50.4 48.5 3.9 % Total net service revenue $260.6 $262.3 (0.6) % % of revenue % of revenue Cost of service 50.6 % $131.8 51.7 % $135.5 (2.7) % Gross margin 49.4 % 128.8 48.3 % 126.8 1.6 % General and administrative expenses 39.5 % 103.0 39.2 % 102.7 0.3 % Total operating expenses 90.1 % $234.8 90.8 % $238.2 (1.4) % Other income — (0.1) Net income attributable to noncontrolling interests 0.6 0.3 Adjusted EBITDA $25.2 $23.9 5.4 % Adjusted EBITDA margin 9.7 % 9.1 % Impairment of goodwill $— $85.8 (100.0) % Net loss attributable to Enhabit, Inc. $(0.2) $(74.4) (99.7) % Reported diluted EPS $— $(1.49) (100.0) % Adjusted EPS (see calculations on slides 34 and 35) $0.07 $0.04 75.0 % General and administrative expenses in the above table exclude: Gain on disposal of assets $— $(0.1) Stock-based compensation expense $2.2 $2.6 Unusual or nonrecurring items that are not typical of ongoing operations(1) $4.8 $2.6 1 Unusual or nonrecurring items in Q2 2024 include costs associated with shareholder activism, the strategic review process and nonroutine litigation; in Q2 2023, they include nonroutine litigation and shareholder activism. Reconciliations to GAAP provided in Appendix

Enhabit Home Health & Hospice 6 Consolidated Results (continued) • 43% of non-Medicare visits are now in payor innovation contracts at improved rates. • Non-Medicare revenue per visit increased to $147. Payor Innovation strategy continues to foster Medicare Advantage growth. Consolidated revenue decreased $1.7 million, or 0.6%, year over year. Reconciliations to GAAP provided in Appendix Continued success in recruitment and retention • Increase of 243 full-time clinical nurses since the spin in 2022 – Highest count of clinical front-line employees since spin Consolidated Adjusted EBITDA grew 5.4% year over year through cost management in home health and revenue growth in hospice.

Enhabit Home Health & Hospice 7 Clinical Expertise and High-Quality Outcomes Enhabit National Average % Better Than Average QoPC Star Rating1 3.4 3.0 13.3% 80% of our home health agencies are 3 Stars or higher; 28% are 4 Stars or higher1 HHCAHPS Star Rating2 3.8 3.6 5.6% 99% of our home health agencies are 3 Stars or higher; 74% are 4 Stars or higher2 30-Day Hospital Readmission Rate3 13.5% 17.6% 23.3% % of patients readmitted to an acute care hospital within 30 days of start of care or resumption of care Patient Visits in Last Days of Life4 73.4% 47.9% 53.2% % of patients who received in person visits from RN or medical social worker on at least two out of the final three days of the patient’s life Standardized Protocols Motivated Clinicians Disciplined Use of Technology Superior Performance ü ü ü ü 1) Quality of Patient Care (QoPC) Star Ratings as of July 2024 for dates of service full year 2022; October 2022 through September 2023 2) Home Health Care Consumer Assessment of Healthcare Providers (HHCAHPS) Patient Survey Star Ratings as of July 2024 for dates of service January 1, 2023 - December 31, 2023 3) Research Institute for Home Care 2023 Chartbook (data from Medicare Standard Analytics Files for CY 2022), Enhabit data is as of Q1 2024 4) Medicare fee for service claims data from January 2021 to December 2022 (source Medicare Provider Data catalog - January 2024)

Enhabit Home Health & Hospice 8 Payor Innovation Payor innovation strategy continues to foster Medicare Advantage growth. Driving steady increases in our non-Medicare revenue per visit 43% of non-Medicare visits are now in payor innovation contracts at improved rates. Visits from payor innovation contracts as a percentage of total non-Medicare visits: Non-Medicare revenue per visit:

Enhabit Home Health & Hospice 9 Payor Innovation (continued) • Improved clinical capacity • Increased favorable payor contracts • negotiated 68 new contracts since spin • Pipeline of 31 new agreements, with 30 historic agreements that are being re-negotiated • Utilizing technology to provide A Better Way to Care and optimize clinical resources • Medalogix Pulse • Virtual care

Enhabit Home Health & Hospice 10 De Novos Strategically reinvesting for growth • Added one home health de novo location in Q2 2024 – Melbourne, Florida home health location began accepting patients in April 2024 Home Health Hospice Total December 31, 2020 241 82 323 De Novo Locations Opened 0 3 3 Acquired Locations 11 11 22 Merged/Closed Locations (1) 0 (1) December 31, 2021 251 96 347 De Novo Locations Opened 1 3 4 Acquired Locations 2 6 8 Merged/Closed Locations (2) 0 (2) December 31, 2022 252 105 357 De Novo Locations Opened 2 4 6 Acquired Locations 1 0 1 YTD 2023 255 109 364 251 252 255 256 96 105 110 112 Home Health Hospice 12/31/21 12/31/22 12/31/23 YTD 2024 0 100 200 300 400 Location Count

Enhabit Home Health & Hospice 11 Home Health Segment ($ in millions) Q2 '24 vs. '232024 2023 Net service revenue: Medicare $121.7 $139.4 (12.7) % Non-Medicare 86.3 71.8 20.2 % Private duty(1) 2.2 2.6 (15.4) % Home health net service revenue 210.2 213.8 (1.7) % Cost of service 106.9 111.4 (4.0) % Gross margin 49.1 % 47.9 % General and administrative expenses 58.6 59.4 (1.3) % Other income — (0.1) (100.0) % Net income attributable to noncontrolling interests 0.5 0.3 66.7 % Adjusted EBITDA $44.2 $42.8 3.3 % % Adj. EBITDA margin 21.0 % 20.0 % Operational metrics (actual amounts) Medicare: Admissions 24,015 26,845 (10.5) % Recertifications 16,639 19,884 (16.3) % Completed episodes 41,620 47,528 (12.4) % Visits 597,742 691,857 (13.6) % Visits per episode 14.4 14.6 (1.4) % Revenue per episode $2,924 $2,933 (0.3) % Non-Medicare: Admissions 30,209 24,130 25.2 % Recertifications 14,587 13,458 8.4 % Visits 581,326 514,008 13.1 % Total: Admissions 54,224 50,975 6.4 % Same-store total admissions growth 6.2 % Recertifications 31,226 33,342 (6.3) % Same-store total recertifications growth (6.5) % Visits 1,179,068 1,205,865 (2.2) % Visits per episode 14.0 14.6 (4.1) % Cost per visit $89 $91 (2.2) % (1)Private duty represents long-term comprehensive hourly nursing medical care. Reconciliations to GAAP provided in Appendix

Enhabit Home Health & Hospice 12 Home Health Segment (continued) Non-Medicare admissions grew 25.2%, driving total admissions growth of 6.4% year over year. • Revenue declined $3.6 million, or 1.7%, year over year primarily due to lower Medicare volume as a result of lower recertifications year over year. – The net impact of the payor mix shift year over year was a positive $1 million. Adjusted EBITDA increased $1.4 million, or 3.3%, year over year primarily due to lower cost per visit. • Cost per visit decreased 2.2% year over year primarily due to a reduction in contract labor and favorable experience in workers' compensation and group medical claims. Home health total admissions increased 6.4% year over year. Reconciliations to GAAP provided in Appendix

Enhabit Home Health & Hospice 13 Hospice Segment ($ in millions) Q2 '24 vs. '232024 2023 Net service revenue $50.4 $48.5 3.9 % Cost of service 24.9 24.1 3.3 % Gross margin 50.6 % 50.3 % General and administrative expenses 16.3 16.1 1.2 % Net income attributable to noncontrolling interests 0.1 — NM Adjusted EBITDA $9.1 $8.3 9.6 % % Adj. EBITDA margin 18.1 % 17.1 % Operational metrics (actual amounts) Total admissions 2,888 2,837 1.8 % Same-store total admissions growth (0.2) % Patient days 320,026 311,465 2.7 % Discharged average length of stay 108 108 — % Average daily census 3,517 3,423 2.7 % Revenue per patient day $157 $156 0.6 % Cost per patient day $78 $77 1.3 % References in the financial tables to percentage changes that are not meaningful are denoted by “NM”. Reconciliations to GAAP provided in Appendix

Enhabit Home Health & Hospice 14 Hospice Segment (continued) Hospice average daily census increased 2.7% year over year. Revenue increased $1.9 million, or 3.9%, year over year due to increased Medicare reimbursement rates and an increase in patient days. • Admissions increased 1.8% year over year. • Revenue per day increased 0.6% year over year primarily due to increased Medicare reimbursement rates. Average daily census increased 3.7% sequentially. • Average daily census increased sequentially every month since January 2024. Adjusted EBITDA increased $0.8 million, or 9.6%, year over year primarily due to increased revenue. • Cost per day increased 1.3% year over year primarily due to increased costs associated with patient supplies, including durable medical equipment and pharmacy. – The impact of merit and market increases was offset by a reduction in contract labor. Reconciliations to GAAP provided in Appendix

Enhabit Home Health & Hospice 15 Consolidated Adjusted EBITDA ($ in millions) Q2 2024 % of Consolidated Revenue Q2 2023 % of Consolidated Revenue Home health segment Adjusted EBITDA $44.2 $42.8 Hospice segment Adjusted EBITDA 9.1 8.3 Home office general & administrative expenses (28.1) 10.8 % (27.2) 10.4 % Consolidated Adjusted EBITDA $25.2 $23.9 Home office general & administrative expenses in the above table exclude: Gain on disposal of assets $— $(0.1) Stock-based compensation $2.2 $2.6 Unusual or nonrecurring items that are not typical of ongoing operations(1) $4.8 $2.6 (1) Unusual or nonrecurring items in Q2 2024 include costs associated with shareholder activism, the strategic review process and nonroutine litigation; in Q2 2023, they include nonroutine litigation and shareholder activism. Reconciliations to GAAP provided in Appendix • Home office general and administrative expenses increased year over year as merit, market and anticipated bonus compensation increases in 2024 offset cost structure changes implemented in the back half of 2023.

Enhabit Home Health & Hospice 16 Debt & Liquidity Metrics ($ in millions) June 30, 2024 December 31, 2023 Advances under revolving credit facility, due 2027(1) $170.0 $180.0 $400 million term loan facility, due 2027(1)(2) 357.5 367.1 Finance lease obligations 8.2 5.5 Total debt $535.7 $552.6 Less: Cash and cash equivalents 28.5 27.4 Net debt $507.2 $525.2 Net debt to Adjusted EBITDA 5.1x 5.4x Trailing twelve-month Adjusted EBITDA $98.9 $97.6 Available liquidity $71.9 $60.8 (1) The Q2 2024 weighted average interest rate was 7.6% (SOFR + credit spread adjustment + 250 bps). (2) In October 2022, Enhabit entered into an interest rate swap to fix the rate on $200 million of its term loan. The swap fixes the SOFR component of the interest rate at 4.3%. Reconciliations to GAAP provided in Appendix In June 2024, the Company made a voluntary $10 million payment, reducing the outstanding balance of the revolving credit facility from $180 million to $170 million.

Enhabit Home Health & Hospice 17 Adjusted Free Cash Flow • Adjusted free cash flow decreased year over year primarily due to cash tax refunds received in 2023 without corresponding refunds in 2024 coupled with higher cash interest payments as a result of higher interest rates year over year. • See Adjusted free cash flow assumptions on slide 20. • See uses of Adjusted free cash flow on slide 21. ($ in millions) $38.9 $1.3 $(4.5) $(5.1)$(0.8) $29.0 Adj. Free Cash Flow YTD 2023 Adjusted EBITDA Change in Working Capital and Other Maintenance Capital Expenditures Cash Interest Payments Cash Tax Payments, Net of Refunds Adj. Free Cash Flow YTD 2024 $0 $10 $20 $30 $40 Reconciliations to GAAP provided in Appendix $(0.8)

Enhabit Home Health & Hospice 18 2024 Guidance Updated as of August 7, 2024 ($ in millions, except per share data) 2023 Actuals 2024 Previous Guidance 2024 Updated Guidance Net service revenue $1,046.3 $1,076 to $1,102 $1,050 to $1,063 Adjusted EBITDA $97.6 $98 to $110 $100 to $106 Adjusted EPS $0.22 $0.12 to $0.43 $0.19 to $0.37 Reconciliations to GAAP provided in Appendix

Enhabit Home Health & Hospice 19 Guidance Considerations • An increase of 1.2% in Medicare pricing • Continued shift to more non-Medicare admissions • Cost per visit increase of 0% to 1% Home Health • An increase of 2.9% in Medicare pricing for Q1 through Q3 • An increase of approximately 3% in Medicare pricing for Q4 • Cost per patient day increase of 2% to 3% Hospice • Tax rate of approximately 26% • Diluted share count of approximately 50.5 million shares Consolidated

Enhabit Home Health & Hospice 20 Adjusted Free Cash Flow Assumptions ($ in millions) Certain cash flow items 2023 Full Year 2024 YTD 2024 Prior Assumptions 2024 Assumptions Adjusted EBITDA $97.6 $50.5 $98 to $110 $100 to $106 Cash interest expense 40.6 22.4 $40 to $45 $41 to $44 Cash income tax payments (refunds), net (8.2) (0.3) $4 to $6 $4 to $5 Working capital and other 3.0 (3.1) $(3) to $3 $(3) to $3 Maintenance capital expenditures 3.4 2.5 $5 to $10 $5 to $10 Adjusted free cash flow $58.8 $29.0 $36 to $62 $39 to $58 • Net cash income tax refunds in 2023 include the impact of a partial refund of 2022 overpayment. Reconciliations to GAAP provided in Appendix

Enhabit Home Health & Hospice 21 Uses of Adjusted Free Cash Flow ($ in millions) Growth in Core Business 2023 Full Year YTD 2024 2024 Assumptions De novos $2.2 $1.0 $2.5 to $3.5 Acquisitions(1) $2.8 $— TBD Debt repayments (borrowings), net $30.0 $20.0 TBD (1) Completed the acquisition of Specialty Home Health Care Inc. in Q1 2023 at a purchase price of $3.1 million, with a hold back of $0.3 million expected to be released March 1, 2025.

Enhabit Home Health & Hospice 22 Appendix

Enhabit Home Health & Hospice 23 Overview 107 hospice locations co-located with home health locations(1) 10 states where we are #1 or #2 in home health(2) ~66% of total Medicare home health spend occurs in states in which we operate(2) Home Health Locations Hospice Locations Home Health & Hospice State Home Health Only State (1) As of June 30, 2024 - due to scale, not all locations can be represented by locational markers (2) Based on 2022 Home Health Medicare revenues 112 Hospice Locations(1) 256 Home Health Locations(1) We are a leading provider of home health and hospice services that strives to provide superior, cost-effective care where patients prefer it: in their homes For over 20 years, we've provided care with high-quality outcomes becoming a trusted partner of health systems, payors and other risk-bearing entities We operate nationally across 34 states with 10,800+ employees We foster an award-winning culture that is a strategic advantage in attracting and retaining talent and a main contributor to our continued success

Enhabit Home Health & Hospice 24 2024 Priorities Home Health Hospice De Novos People Strategy • Stabilize Medicare as a % of total home health revenue • Leverage payor innovation strategy – Improve Medicare Advantage rates – Shift away from lower rate contracts • Grow through increased clinical staffing, ability to accept new payors and alignment of clinical resource utilization with patient acuity and complexities • Grow census through improved staffing capacity with case management model • Gain operating leverage in hospice fixed cost structure by growing census • Increase use of analytics to drive high-quality care via case management model • Focus on efficiencies in referral to admission process • Open 10 de novo locations • Ramp up staffing, referral and admission growth in de novo locations opened in 2023 • Continue to increase net full-time nursing and therapy headcount to support home health growth • Focus on employee engagement to retain workforce

Enhabit Home Health & Hospice 25 Long-Term Outlook

Enhabit Home Health & Hospice 26 Enhabit Home Health Long-Term Outlook Q2 2024 home health admissions continued to grow versus prior year, and we expect to continue growing at mid- to high- single digits over the next three years with our ability to better serve referral sources through improved clinical capacity and payor innovation contracts. Home health admissions have accelerated over the last three quarters Home Health Admissions Growth vs Prior Year 1.2% 3.2% 1.6% 3.9% 5.3% 6.4% —% 1.7% 0.2% 3.2% 5.0% 6.2% Total admissions growth Same-store admissions growth Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24

Enhabit Home Health & Hospice 27 Enhabit Hospice Long-Term Outlook Expect hospice volumes to grow at mid- to high-single digits over the next three years after investing in the case management model and the build out of business development team Sequential monthly growth in census in 2024 2024 Hospice Monthly Census Trend 3,343 3,368 3,459 3,491 3,520 3,539 Jan-24 Feb-24 Mar-24 Apr-24 May-24 Jun-24

Enhabit Home Health & Hospice 28 Home Health Operational Metrics (net service revenue $ in millions) Q1 2023 Q2 2023 Q3 2023 Q4 2023 FY 2023 Q1 2024 Q2 2024 YTD 2024 Medicare $146.0 $139.4 $141.0 $130.9 $557.3 $128.3 $121.7 $250.0 Non-Medicare 67.1 71.8 67.3 76.8 283.0 82.6 86.3 168.9 Private duty(1) 2.7 2.6 2.6 1.8 9.7 2.3 2.2 4.5 Home health net service revenue $215.8 $213.8 $210.9 $209.5 $850.1 $213.2 $210.2 $423.4 (actual amounts)(1) Medicare: Admissions 29,285 26,845 25,585 25,090 106,805 25,944 24,015 49,959 Recertifications 19,938 19,884 19,321 18,970 78,113 17,652 16,639 34,291 Completed episodes 49,231 47,528 44,350 44,305 185,414 43,171 41,620 84,791 Visits 723,399 691,857 660,380 639,744 2,715,380 632,047 597,742 1,229,789 Visits per episode 14.7 14.6 14.9 14.4 14.6 14.6 14.4 14.5 Revenue per episode $ 2,966 $ 2,933 $ 3,179 $ 2,955 $ 3,006 $ 2,972 $ 2,924 $ 2,948 Non-Medicare: Admissions 24,658 24,130 24,938 26,917 100,643 30,881 30,209 61,090 Recertifications 11,840 13,458 13,411 13,058 51,767 13,489 14,587 28,076 Visits 482,301 514,008 501,764 522,641 2,020,714 571,289 581,326 1,152,615 Total: Admissions 53,943 50,975 50,523 52,007 207,448 56,825 54,224 111,049 Recertifications 31,778 33,342 32,732 32,028 129,880 31,141 31,226 62,367 Visits 1,205,700 1,205,865 1,162,144 1,162,385 4,736,094 1,203,336 1,179,068 2,382,404 Visits per episode 14.8 14.6 14.9 14.3 14.6 14.9 14.0 14.5 Cost per visit $ 88 $ 91 $ 93 $ 92 $ 91 $ 90 $ 89 $ 90 (1) Private duty represents long-term comprehensive hourly nursing medical care.

Enhabit Home Health & Hospice 29 Hospice Operational Metrics (net service revenue $ in millions) Q1 2023 Q2 2023 Q3 2023 Q4 2023 FY 2023 Q1 2024 Q2 2024 YTD 2024 Hospice net service revenue $49.3 $48.5 $47.4 $51.1 $196.2 $49.2 $50.4 $99.6 (actual amounts) Total admissions 3,122 2,837 2,882 2,872 11,713 3,032 2,888 5,920 Patient days 317,027 311,465 311,719 315,870 1,256,081 308,542 320,026 628,568 Discharged average length of stay 114 108 107 102 108 104 108 106 Average daily census 3,523 3,423 3,388 3,433 3,441 3,391 3,517 3,454 Revenue per day $156 $156 $152 $162 $156 $159 $157 $158 Cost per day $77 $77 $77 $76 $77 $79 $78 $78

Enhabit Home Health & Hospice 30 Consolidated Results – Year to Date 2024 ($ in millions, except per share data) Year-To-Date '24 vs. '232024 2023 Home health net service revenue $423.4 $429.7 (1.5) % Hospice net service revenue 99.6 97.7 1.9 % Total net service revenue $523.0 $527.4 (0.8) % % of Revenue % of Revenue Cost of service 50.9 % 266.0 50.8 % 268.1 (0.8) % Gross margin 49.1 % 257.0 49.2 % 259.3 (0.9) % General and administrative expenses 39.2 % 205.2 39.7 % 209.4 (2.0) % Total operating expenses 90.1 % 471.2 90.5 % 477.5 (1.3) % Other income — (0.1) Net income attributable to noncontrolling interests 1.3 0.8 Adjusted EBITDA $50.5 $49.2 2.6 % Adjusted EBITDA margin 9.7 % 9.3 % Impairment of goodwill $— $85.8 (100.0) % Net loss attributable to Enhabit, Inc. $— $(71.7) (100.0) % Reported diluted EPS $— $(1.44) (100.0) % Adjusted EPS (see calculations on slides 36 and 37) $0.14 $0.14 — % General and administrative expenses in the above table exclude: Gain on disposal of assets $(0.2) $(0.1) Stock-based compensation expense $4.0 $4.1 Unusual or nonrecurring items that are not typical of ongoing operations(1) $8.5 $4.9 (1) Unusual or nonrecurring items in 2024 include costs associated with shareholder activism, the strategic review process and nonroutine litigation; in 2023, they include costs associated with nonroutine litigation and shareholder activism. Reconciliations to GAAP provided in Appendix

Enhabit Home Health & Hospice 31 Home Health Segment Results – YTD 2024 ($ in millions) Year-To-Date '24 vs. '232024 2023 Net service revenue: Medicare $250.0 $285.5 (12.4) % Non-Medicare 169.0 138.9 21.7 % Private duty(1) 4.4 5.3 (17.0) % Home health net service revenue 423.4 429.7 (1.5) % Cost of service 216.8 219.5 (1.2) % Gross margin 48.8 % 48.9 % General and administrative expenses 118.1 122.3 (3.4) % Other income — (0.1) (100.0) % Net income attributable to noncontrolling interests 1.1 0.8 37.5 % Adjusted EBITDA $87.4 $87.2 0.2 % % Adj. EBITDA margin 20.6 % 20.3 % Operational metrics (actual amounts) Medicare: Admissions 49,959 56,130 (11.0) % Recertifications 34,291 39,822 (13.9) % Completed episodes 84,791 96,759 (12.4) % Visits 1,229,789 1,415,256 (13.1) % Visits per episode 14.5 14.6 (0.7) % Revenue per episode $2,948 $2,951 (0.1) % Non-Medicare: Admissions 61,090 48,788 25.2 % Recertifications 28,076 25,298 11.0 % Visits 1,152,615 996,309 15.7 % Total: Admissions 111,049 104,918 5.8 % Same-store total admissions growth 5.6 % Recertifications 62,367 65,120 (4.2) % Same-store total recertifications growth (4.5) % Visits 2,382,404 2,411,565 (1.2) % Visits per episode 14.5 14.7 (1.4) % Cost per visit $90 $89 1.1 % (1) Private duty represents long-term comprehensive hourly nursing medical care. Reconciliations to GAAP provided in Appendix

Enhabit Home Health & Hospice 32 Hospice Segment Results – YTD 2024 ($ in millions) Year-To-Date '24 vs. '232024 2023 Net service revenue $99.6 $97.7 1.9 % Cost of service 49.2 48.6 1.2 % Gross margin 50.6 % 50.3 % General and administrative expenses 32.0 32.4 (1.2) % Net income attributable to noncontrolling interests 0.2 — NM Adjusted EBITDA $18.2 $16.7 9.0 % % Adj. EBITDA margin 18.3 % 17.1 % Operational metrics (actual amounts) Total admissions 5,920 5,959 (0.7) % Same-store total admissions growth (3.0) % Patient days 628,568 628,492 — % Discharged average length of stay 106 111 (4.5) % Average daily census 3,454 3,472 (0.5) % Revenue per patient day $158 $155 1.9 % Cost per patient day $78 $77 1.3 % References in the financial tables to percentage changes that are not meaningful are denoted by “NM”. Reconciliations to GAAP provided in Appendix

Enhabit Home Health & Hospice 33 Payor Sources As a % of Revenue Q2 Year-To-Date Fiscal Year Consolidated 2024 2023 2024 2023 2023 Medicare 65.7% 70.8% 66.5% 71.9% 71.5% Medicare Advantage 23.5% 20.3% 23.1% 19.5% 19.0% Managed Care 9.6% 7.7% 9.3% 7.5% 8.2% Medicaid 1.0% 1.2% 0.9% 1.1% 1.2% Other 0.2% —% 0.2% —% 0.1% Total 100.0% 100.0% 100.0% 100.0% 100.0% Home Health Medicare 57.9% 65.2% 59.0% 66.4% 65.6% Medicare Advantage 29.2% 24.9% 28.5% 24.0% 23.4% Managed Care 11.5% 8.5% 11.0% 8.2% 9.5% Medicaid 1.1% 1.4% 1.2% 1.3% 1.4% Other 0.3% —% 0.3% 0.1% 0.1% Total 100.0% 100.0% 100.0% 100.0% 100.0% Hospice Medicare 98.2% 95.3% 98.1% 96.0% 97.1% Managed Care 1.8% 4.1% 1.9% 4.0% 2.5% Medicaid —% 0.4% —% —% 0.4% Other —% 0.2% —% —% —% Total 100.0% 100.0% 100.0% 100.0% 100.0%

Enhabit Home Health & Hospice 34 EPS Calculation: Q2 2024 ($ in millions, except per share amounts) Adjusted EPS – Q2 2024 As Reported Unusual or Nonrecurring Items That are Not Typical of Ongoing Operations As Adjusted Adjusted EBITDA(1) $25.2 $— $25.2 Interest expense and amortization of debt discounts and fees (10.9) — (10.9) Depreciation and amortization (7.6) — (7.6) Stock-based compensation (2.2) — (2.2) Unusual or nonrecurring items that are not typical of ongoing operations(2) (4.8) 4.8 — (Loss) income before income taxes (0.3) 4.8 4.5 Income tax benefit (expense) 0.1 (1.3) (1.2) Net (loss) income attributable to Enhabit, Inc. $(0.2) $3.5 $3.3 Diluted EPS $— $0.07 $0.07 Diluted shares 50.1 50.1 (1) Reconciliation to GAAP provided on slides 38 and 39. (2) Unusual or nonrecurring items in Q2 2024 include costs associated with shareholder activism, the strategic review process and nonroutine litigation.

Enhabit Home Health & Hospice 35 EPS Calculation: Q2 2023 ($ in millions, except per share amounts) Adjusted EPS – Q2 2023 As Reported Impairment of Goodwill Unusual or Nonrecurring Items That are Not Typical of Ongoing Operations Income Tax Adjustments(3) As Adjusted Adjusted EBITDA(1) $23.9 $— $— $— $23.9 Interest expense and amortization of debt discounts and fees (10.3) — — — (10.3) Depreciation and amortization (7.7) — — — (7.7) Gain on disposal of assets 0.1 — — — 0.1 Impairment of goodwill (85.8) 85.8 — — — Stock-based compensation (2.6) — — — (2.6) Unusual or nonrecurring items that are not typical of ongoing operations(2) (2.6) — 2.6 — — (Loss) income before income taxes (85.0) 85.8 2.6 — 3.4 Income tax benefit (expense) 10.6 (11.1) (1.0) 0.1 (1.4) Net (loss) income attributable to Enhabit, Inc. $(74.4) $74.7 $1.6 $0.1 $2.0 Diluted EPS $(1.49) $1.50 $0.03 $— $0.04 Diluted shares 49.8 49.8 (1) Reconciliation to GAAP provided on slides 38 and 39. (2) Unusual or nonrecurring items in Q2 2023 include costs associated with nonroutine litigation and shareholder activism. (3) Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation.

Enhabit Home Health & Hospice 36 EPS Calculation: YTD 2024 ($ in millions, except per share amounts) Adjusted EPS – YTD 2024 As Reported Unusual or Nonrecurring Items That are Not Typical of Ongoing Operations Income Tax Adjustments(3) As Adjusted Adjusted EBITDA(1) $50.5 $— $— $50.5 Interest expense and amortization of debt discounts and fees (22.0) — — (22.0) Depreciation and amortization (15.4) — — (15.4) Gain on disposal of assets 0.2 — — 0.2 Stock-based compensation (4.0) — — (4.0) Unusual or nonrecurring items that are not typical of ongoing operations(2) (8.5) 8.5 — — Income before income taxes 0.8 8.5 — 9.3 Income tax expense (0.8) (2.2) 0.6 (2.4) Net income attributable to Enhabit, Inc. $— $6.3 $0.6 $6.9 Diluted EPS $— $0.13 $0.01 $0.14 Diluted shares 50.1 50.1 (1) Reconciliation to GAAP provided on slides 38 and 39. (2) Unusual or nonrecurring items in 2024 include costs associated with shareholder activism, the strategic review process and nonroutine litigation. (3) Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation.

Enhabit Home Health & Hospice 37 EPS Calculation: YTD 2023 ($ in millions, except per share amounts) Adjusted EPS – FY 2023 As Reported Impairment of Goodwill Unusual or Nonrecurring Items That are Not Typical of Ongoing Operations Income Tax Adjustments(3) As Adjusted Adjusted EBITDA(1) $49.2 $— $— $— $49.2 Interest expense and amortization of debt discounts and fees (19.8) — — — (19.8) Depreciation and amortization (15.5) — — — (15.5) Gain on disposal of assets 0.1 — — — 0.1 Impairment of goodwill (85.8) 85.8 — — — Stock-based compensation (4.1) — — — (4.1) Unusual or nonrecurring items that are not typical of ongoing operations(2) (4.9) — 4.9 — — (Loss) income before income taxes (80.8) 85.8 4.9 — 9.9 Income tax benefit (expense) 9.1 (11.1) (1.6) 0.5 (3.1) Net (loss) income attributable to Enhabit, Inc. $(71.7) $74.7 $3.3 $0.5 $6.8 Diluted EPS $(1.44) $1.50 $0.07 $0.01 $0.14 Diluted shares 49.8 49.8 (1) Reconciliation to GAAP provided on slides 38 and 39. (2) Unusual or nonrecurring items in 2023 include costs associated with nonroutine litigation and shareholder activism. (3) Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation.

Enhabit Home Health & Hospice 38 Reconciliation of Net Income (Loss) to Adjusted EBITDA – Consolidated ($ in millions) Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Net income (loss) $0.4 $(74.1) $1.3 $(70.9) Interest expense and amortization of debt discounts and fees 10.9 10.3 22.0 19.8 Income tax (benefit) expense (0.1) (10.6) 0.8 (9.1) Depreciation and amortization 7.6 7.7 15.4 15.5 Gain on disposal of assets — (0.1) (0.2) (0.1) Impairment of goodwill — 85.8 — 85.8 Stock-based compensation 2.2 2.6 4.0 4.1 Net income attributable to noncontrolling interests (0.6) (0.3) (1.3) (0.8) Unusual or nonrecurring items that are not typical of ongoing operations(1) 4.8 2.6 8.5 4.9 Adjusted EBITDA $25.2 $23.9 $50.5 $49.2 (1) Unusual or nonrecurring items in the three and six months ended June 30, 2024 include costs associated with shareholder activism, the strategic review process and nonroutine litigation; in the three and six months ended June 30, 2023, they include nonroutine litigation and shareholder activism.

Enhabit Home Health & Hospice 39 Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA ($ in millions) Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Net cash provided by operating activities $9.6 $9.6 $26.9 $39.2 Interest expense, excluding amortization of debt discounts and fees 10.6 10.1 21.3 19.3 Current portion of income tax expense 0.5 0.7 1.9 1.9 Change in assets and liabilities, excluding derivative instrument 0.3 1.2 (6.9) (15.0) Net income attributable to noncontrolling interests (0.6) (0.3) (1.3) (0.8) Unusual or nonrecurring items that are not typical of ongoing operations(1) 4.8 2.6 8.5 4.9 Other — — 0.1 (0.3) Adjusted EBITDA $25.2 $23.9 $50.5 $49.2 (1) Unusual or nonrecurring items in the three and six months ended June 30, 2024 include costs associated with shareholder activism, the strategic review process and nonroutine litigation; in the three and six months ended June 30, 2023, they include nonroutine litigation and shareholder activism.

Enhabit Home Health & Hospice 40 Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow ($ in millions) Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Net cash provided by operating activities $9.6 $9.6 $26.9 $39.2 Unusual or nonrecurring items that are not typical of ongoing operations(1) 4.8 2.6 8.5 4.9 Capital expenditures for maintenance (0.7) (1.1) (2.5) (1.7) Other working capital adjustments (1.1) (0.5) (1.7) (1.0) Distributions paid to noncontrolling interests of consolidated affiliates (2.2) — (2.2) (2.5) Adjusted free cash flow $10.4 $10.6 $29.0 $38.9 (1) Unusual or nonrecurring items in the three and six months ended June 30, 2024 include costs associated with shareholder activism, the strategic review process and nonroutine litigation; in the three and six months ended June 30, 2023, they include nonroutine litigation and shareholder activism.

Enhabit Home Health & Hospice 41 Reconciliation of Gross Margin to Adjusted EBITDA Margin Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Gross margin as a percentage of revenue 49.4 % 48.3 % 49.1 % 49.2 % General and administrative expenses (42.2) % (41.1) % (41.6) % (41.4) % Stock-based compensation 0.9 % 1.0 % 0.8 % 0.8 % Noncontrolling interests (0.2) % (0.1) % (0.2) % (0.2) % Unusual or nonrecurring items that are not typical of ongoing operations(1) 1.8 % 1.0 % 1.6 % 0.9 % Adjusted EBITDA margin 9.7 % 9.1 % 9.7 % 9.3 % (1) Unusual or nonrecurring items in the three and six months ended June 30, 2024 include costs associated with shareholder activism, the strategic review process and nonroutine litigation; in the three and six months ended June 30, 2023, they include nonroutine litigation and shareholder activism.

Cover	Aug. 06, 2024
Cover [Abstract]
Document Type	8-K
Document Period End Date	Aug. 06, 2024
Entity Registrant Name	Enhabit, Inc.
Entity Incorporation, State or Country Code	DE
Entity File Number	001-41406
Entity Tax Identification Number	47-2409192
Entity Address, Address Line One	6688 N. Central Expressway
Entity Address, Address Line Two	Suite 1300
Entity Address, City or Town	Dallas
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	75206
City Area Code	214
Local Phone Number	239-6500
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	EHAB
Security Exchange Name	NYSE
Entity Emerging Growth Company	false
Amendment Flag	false
Entity Central Index Key	0001803737